JGJuliana González-Sanmiguel

Juliana González-Sanmiguel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Juliana González-Sanmiguel has a total of 124 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Alterations in neuronal excitability and AMPA-mediated neurotransmission in an APP/PS1 neuronal culture model derived from nucleus accumbens

    by Paulina Saavedra-Sieyes, Isaías Meza, Nicolás Riffo-Lepe, Loreto San Martin, Juliana González-SanMiguel, Luis G Aguayo

    Alzheimer's disease is a neurodegenerative disease. Recently, alterations in the mesolimbic system have been described, especially in the nucleus accumbens (nAc). We found that intracellular accumulation of Aβ was higher in neurons of the APP/PS1 mice at 10 and 15 days in vitro . At 15 days in vitro (DIV), APP/PS1 accumbal neurons showed alterations in synaptic transmission and neuronal excitability. Specifically, there was an increase in AMPAergic synaptic currents, which was sensitive to the application of NASPM, suggesting a critical role for calcium-permeable AMPA receptors (CP-AMPARs). Our study indicates that this neuronal culture model accurately replicates alterations in the early stages of AD.


  • Contributors

    by Luis G. Aguayo, Marium Ahmed, Mohamed H. Ahmed, Musaab Ahmed, Hélio M.T. Albuquerque, Alicia Alonso, Rana Ashkar, Fodil Azzaz, Carlos J. Baier, Francisco J. Barrantes, et al.

  • Open Access

    Complex Interaction between Resident Microbiota and Misfolded Proteins: Role in Neuroinflammation and Neurodegeneration

    by Juliana González-Sanmiguel, Christina M. A. P. Schuh, Carola Muñoz-Montesino, Pamina Contreras-Kallens, Luis G. Aguayo, Sebastian Aguayo

    Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Creutzfeldt–Jakob disease (CJD) are brain conditions affecting millions of people worldwide. These diseases are associated with the presence of amyloid-β (Aβ), alpha synuclein (α-Syn) and prion protein (PrP) depositions in the brain, respectively, which lead to synaptic disconnection and subsequent progressive neuronal death. Although considerable progress has been made in elucidating the pathogenesis of these diseases, the specific mechanisms of their origins remain largely unknown. A body of research suggests a potential association between host microbiota, neuroinflammation and dementia, either directly due to bacterial brain invasion because of barrier leakage and production of toxins and inflammation, or indirectly by modulating the immune response. In the present review, we focus on the emerging topics of neuroinflammation and the association between components of the human microbiota and the deposition of Aβ, α-Syn and PrP in the brain. Special focus is given to gut and oral bacteria and biofilms and to the potential mechanisms associating microbiome dysbiosis and toxin production with neurodegeneration. The roles of neuroinflammation, protein misfolding and cellular mediators in membrane damage and increased permeability are also discussed.


  • Gabapentin Inhibits Multiple Steps in the Amyloid Beta Toxicity Cascade

    by Juliana González-Sanmiguel, Carlos F. Burgos, Denisse Bascuñán, Eduardo J. Fernández-Pérez, Nicolás Riffo-Lepe, Subramanian Boopathi, Arturo Fernández-Pérez, Catalina Bobadilla-Azócar, Wendy González, Maximiliano Figueroa, et al.

    Oligomeric β amyloid peptide (Aβ) is one of the main neurotoxic agents of Alzheimer´s disease (AD). Oligomers associate to neuronal membranes forming “pore-like” structures that cause intracellular calcium and neurotransmitter dyshomeostasis, leading to synaptic failure and death. Through molecular screening targeting the C terminal region of Aβ, a region involved in the toxic properties of the peptide, we detected an FDA approved compound, gabapentin (GBP), with neuroprotective effects against Aβ toxicity. At micromolar concentrations, GBP antagonized peptide aggregation over time and reduced the Aβ absorbance plateau to 28% of control. In addition, GBP decreased Aβ association to membranes by almost half, and the effects of Aβ on intracellular calcium in hippocampal neurons were antagonized without causing effects on its own. Finally, we found that GBP was able to block the synaptotoxicity induced by Aβ in hippocampal neurons increasing postsynaptic currents from 1.7±0.9 to 4.2±0.7 fC, and mean relative fluorescence intensity values of SV2, a synaptic protein, from 0.7±0.09 to 1.00±0.08. The results show that GBP can interfere with Aβ-induced toxicity by blocking multiple steps resulting in neuroprotection and justifies advancing towards additional animal and human studies.


  • Open Access

    Characterization of a new molecule capable of inhibiting several steps of the amyloid cascade in Alzheimer's disease

    by Christian Peters, Denisse Bascuñán, Carlos F. Burgos, Catalina Bobadilla, Juliana González-Sanmiguel, Subramanian Boopathi, Nicolás Riffo, Eduardo J. Fernández-Pérez, María Elena Tarnok, Luis Felipe Aguilar, et al.


  • Open Access

    Effect of Cholesterol on Membrane Fluidity and Association of Aβ Oligomers and Subsequent Neuronal Damage: A Double-Edged Sword

    by Eduardo J. Fernández-Pérez, Fernando J. Sepúlveda, Christian Peters, Denisse Bascuñán, Nicolás O. Riffo-Lepe, Juliana González-Sanmiguel, Susana A. Sánchez, Robert W. Peoples, Benjamín Vicente, Luis G. Aguayo

    Background: The beta-amyloid peptide (Aβ) involved in Alzheimer’s disease (AD) has been described to associate/aggregate on the cell surface disrupting the membrane through pore formation and breakage. However, molecular determinants involved for this interaction (e.g., some physicochemical properties of the cell membrane) are largely unknown. Since cholesterol is an important molecule for membrane structure and fluidity, we examined the effect of varying cholesterol content with the association and membrane perforation by Aβ in cultured hippocampal neurons. Methods: To decrease or increase the levels of cholesterol in the membrane we used methyl-β-cyclodextrin (MβCD) and MβCD/cholesterol, respectively. We analyzed if membrane fluidity was affected using generalized polarization (GP) imaging and the fluorescent dye di-4-ANEPPDHQ. Additionally membrane association and perforation was assessed using immunocytochemistry and electrophysiological techniques, respectively. Results: The results showed that cholesterol removal decreased the macroscopic association of Aβ to neuronal membranes (fluorescent-puncta/20 μm: control = 18 ± 2 vs. MβCD = 10 ± 1, p < 0.05) and induced a facilitation of the membrane perforation by Aβ with respect to control cells (half-time for maximal charge transferred: control = 7.2 vs. MβCD = 4.4). Under this condition, we found an increase in membrane fluidity (46 ± 3.3% decrease in GP value, p < 0.001). On the contrary, increasing cholesterol levels incremented membrane rigidity (38 ± 2.7% increase in GP value, p < 0.001) and enhanced the association and clustering of Aβ (fluorescent-puncta/20 μm: control = 18 ± 2 vs. MβCD = 10 ± 1, p < 0.01), but inhibited membrane disruption. Conclusion: Our results strongly support the significance of plasma membrane organization in the toxic effects of Aβ in hippocampal neurons, since fluidity can regulate distribution and insertion of the Aβ peptide in the neuronal membrane.


  • PDGF-BB Preserves Mitochondrial Morphology, Attenuates ROS Production, and Upregulates Neuroglobin in an Astrocytic Model Under Rotenone Insult

    by Ricardo Cabezas, Nelson E. Vega-Vela, Juliana González-Sanmiguel, Janneth González, Paula Esquinas, Valentina Echeverria, George E. Barreto

    Platelet-derived growth factor, subtype BB (PDGF-BB) is a mitogenic growth factor produced in different cell types such as platelets, fibroblasts, neurons, and astrocytes. Previous reports have shown that different PDGF isoforms exert a neuroprotective effect in neurons and astrocytes against multiple degenerative insults. Previously, we showed that pretreatment with PDGF-BB for 24 h increased cell viability, preserved nuclear morphology and mitochondrial membrane potential following stimulation with rotenone, and reduced free radical production nearly to control conditions. In the present study, we explored the potential mechanisms associated with PDGF-BB protection against oxidative damage. Our results showed that PDGF-BB protected astrocytic cells through multiple responses, including decrease in the expression of cytoskeleton proteins, attenuated free radicals (reactive oxygen species (ROS)) production, preservation of mitochondrial ultrastructure, and improved expression of neuroglobin (Ngb1). In summary, these findings point out that PDGF-BB protects astrocytic cells by a reduction in ROS production and activation of antioxidant mechanisms.